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Abstract: Surgical organizations dedicated to the improvement of patient outcomes have led to a
worldwide paradigm shift in perioperative patient care. Since 2012, the Enhanced Recovery After
Surgery (ERAS®) Society has published guidelines pertaining to perioperative care in numerous
disciplines including elective colorectal and gynecologic/oncology surgery patients. The ERAS®
and ERAS-USA® Societies use standardized methodology for collecting and assessing various
surgical parameters in real-time during the operative process. These multi-disciplinary groups
have constructed a bundled framework of perioperative care that entails 22 specific components
of clinical interventions, which are logged in a central database, allowing a system of audit and
feedback. Of these 22 recommendations, nine of them specifically involve the use of medications
or pharmacotherapy. This retrospective comparative pharmacotherapy project will address the
potential need to (1) collect more specific pharmacotherapy data within the existing ERAS Interactive
Audit System® (EIAS) program, (2) understand the relationship between medication regimen and
patient outcomes, and (3) minimize variability in pharmacotherapy use in the elective colorectal and
gynecologic/oncology surgical cohort. Primary outcomes measures include data related to surgical
site infections, venous thromboembolism, and post-operative nausea and vomiting as well as patient
satisfaction, the frequency and severity of post-operative complications, length of stay, and hospital
re-admission at 7 and 30 days, respectively. The methodology of this collaborative research project
is described.
Keywords: collaboration; enhanced recovery; infection, surgical wound; perioperative care; pharmacy,
clinical; post-operative nausea and vomiting; prophylaxis; surgeon; surgery; colorectal; surgery;
gynecological; thromboembolism; venous
1. Introduction
Since 2012, the Enhanced Recovery After Surgery (ERAS®) Society has published guidelines
pertaining to perioperative care in numerous disciplines including elective colorectal [1] and
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gynecologic/oncology [2–4] surgery patients. These bundled guidelines contain recommendations
on the use of pharmacologic therapy, including prophylaxis for (1) surgical site infection (SSI),
(2) thromboembolism (VTE), and (3) postoperative nausea and vomiting (PONV), among others.
While the guidelines contain high-quality evidence of the use of pharmacotherapy in each of these
ERAS program elements, the specifics of agent selection and dosing regimens are absent. These dosing
variables include medication administration time in relation to the procedure, dose of medication used,
and duration of therapy. The literature suggests that the lack of effective prophylaxis to address these
three endpoints is associated with significant clinical morbidity, and they may be independent drivers
of hospital length of stay. Suboptimal preventive pharmacotherapy may lead to increased complication
rates and delayed patient discharge from the facility.
The ERAS® and ERAS-USA® Societies use a standardized methodology for collecting and
assessing various surgical parameters in real-time during the operative process [5]. By utilizing
a retrospective multi-center research design, this project will address the potential need to (1) collect more
specific pharmacotherapy data within the existing ERAS Interactive Audit System® (EIAS) program,
(2) understand the relationship between medication regimen and patient outcomes, and (3) minimize
variability in pharmacotherapy use in the elective colorectal and gynecologic/oncology surgical cohort.
The specific aims of this project include:
1. Creation of a pharmacotherapy database and execution of a retrospective analysis to compile
perioperative medication-specific data related to significant improvements in patient outcomes.
2. Estimation of the impact of prophylaxis medications on length of stay, postoperative complications,
and hospital readmission rates at 7 and 30 days for the following indications:
a. Surgical site infections;
b. Thromboembolism;
c. Post-operative nausea and vomiting.
3. Provide guidance on optimal medication use regarding regimen selection, dosing, timing,
and duration of therapy.
2. Research Strategy
The development and evolution of Enhanced Recovery Programs have led to significant
improvements in the care of surgical patients, as well as a decrease in important benchmarks such as
hospital length of stay (LOS) and postoperative complications [6]. As a result, surgical organizations
dedicated to the improvement of patient outcomes have led a paradigm shift in perioperative patient
care. Specific groups, like the Enhanced Recovery After Surgery (ERAS®) Society and ERAS® USA,
have constructed a bundled framework of care entailing 22 specific components of perioperative
clinical interventions, which are logged in a central database, allowing a system of audit and
feedback. Of these 22 recommendations, nine of them specifically involve the use of medications or
pharmacotherapy. They include the following: (1) pre-anesthetic medication; (2) prophylaxis against
venous thromboembolism (VTE); (3) antimicrobial prophylaxis and skin preparation; (4) standard
anesthetic protocol; (5) post-operative nausea and vomiting (PONV) prophylaxis; (6) perioperative
fluid management; (7) prevention of postoperative ileus (including use of postoperative laxatives);
(8) postoperative analgesia, and (9) postoperative glucose control [7]. While these recommendations
address global concepts of perioperative patient care, the ERAS protocols do not specify particular
pharmacotherapeutic medication classes, agents, or doses. As a result of the inherent variability in
medication use, the optimal pharmacotherapeutic agents within ERAS® pathways are unknown.
Furthermore, variance in the timing of medication administration leaves practitioners searching for the
exact method of replicating the significant outcomes found in ERAS publications.
In its current form, EIAS® collects limited information related to medication administration for
ERAS® patients. Despite this dearth, patient outcomes have consistently improved in institutions that
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have adopted ERAS® pathways. Whether these improvements are due to individual therapeutic agents
or the application of a bundled approach is unknown. Practitioners and pharmacists are challenged to
make evidence-based pharmacotherapeutic recommendations of agents within the protocol. Inevitably,
debates on implementation often center on more costly versions of medications such as intravenous
acetaminophen or liposomal bupivacaine as means to limit opioid use.
We plan to integrate de-identified patient data from two separate ERAS® centers in North America
with pharmacotherapy data collected retrospectively from each site. From this registry, we will seek
answers to comparative pharmacotherapy questions embedded in the ERAS® pathway. Specifically,
we plan to evaluate the following: (1) timing of preoperative and post-operative thromboprophylaxis
and the impact on post-operative VTE; (2) specific agents and doses of antimicrobials used in surgical
antimicrobial prophylaxis, and (3) optimal and efficacious regimens in the successful prevention
of PONV.
3. Approach
Our Enhanced Recovery Comparative Pharmacotherapy Collaborative (ERCPC) group plans
to evaluate the role that specific pharmacotherapeutic regimens within the ERAS® protocol play in
regard to the improved outcomes, readmission, and hospital LOS. In addition, data regarding patient
experience or satisfaction scores will be collected. This information will be obtained through patient
registry of the EIAS®. The two institutions that have provided written support for access to their
patients’ data are the Foothills Medical Centre (FMC) of Calgary, Alberta, Canada and the Brigham
& Women’s Hospital of Boston, MA, USA. Both institutions have robust ERAS® practices and are
leading researchers in the practice of enhanced surgical recovery.
Data from patient healthcare records at each site will be collected and entered into a centralized
REDCap database. The project’s data dictionary is included in a Supplementary Material File
attachment. Patient demographics, intraoperative anesthetic techniques, and procedure details will
also be collected. Drug-related variables will be compared to determine the effect of agent use on
outcome measures. Potential hurdles that we anticipate are low event rates with some primary
outcomes measures, specifically VTE. Recent literature suggests that the incidence of VTE in colorectal
surgery patients is approximately 2.2% [8,9]. While a population of 500 colorectal patients would
have an estimated incidence of 11 cases, we may be challenged to obtain a difference between groups
if numerous different regimens are used. Gynecologic and colorectal malignancy patients show a
similarly low incidence; however, it is slightly higher at approximately 3% [10] and is purported to
be on the rise [11]. By combining the two patient populations, we estimate a sufficient number of
thromboembolic events from which we will be able to ascertain a statistical difference. Additionally,
because we will be evaluating the pharmacotherapeutic interventions from ERAS®, it is possible that
ERAS® components not captured in our analysis may play more significant roles in reducing negative
outcomes compared to the agents that we evaluate. However, if no difference is found, this may too
provide justification for the use of different regimens within the ERAS pathway. Finally, we have
strong physician support from experienced researchers who are eager to participate in this project.
4. Specific Research Questions
1. Determine the optimal antimicrobial agents used in surgical prophylaxis, including pre-operative
dose, timing of preoperative dose, intraoperative repeat doses, postoperative duration of therapy,
classification of surgical site infection (if present), and infection organism (if applicable) [12].
2. Provide evidence to define optimal prophylaxis regimens to prevent PONV in this surgical population.
Specific parameters of analysis include PONV risk factors, preoperative Apfel risk score [13],
prophylaxis regimen (dose, timing), postoperative nausea, and duration of Post Anesthesia Care
Unit (PACU) LOS [14].
3. Evaluate the effect that venous thromboembolism (VTE) prophylaxis provides in preventing
post-operative VTE in high-risk oncology populations. Specific points of evaluation include
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prophylaxis agent used (unfractionated heparin versus low-molecular weight heparin verses
direct thrombin inhibitors), perioperative timing of dose, post-operative duration of therapy,
thromboembolic risk factors, and patient weight [15,16].
5. Conclusions
Our ERCPC group plans to evaluate the impact that specific pharmacotherapeutic regimens
within the ERAS® protocol have on primary clinical outcomes (surgical site infections,
venous thromboembolism, and post-operative nausea and vomiting) as well as their relationship
to and impact on readmission, complications, and hospital LOS. We plan to integrate de-identified
patient data from two separate ERAS® centers in North America with pharmacotherapy data collected
retrospectively from each site. From this registry, we will seek answers to comparative pharmacotherapy
questions embedded in the ERAS® pathway. Specifically, we plan to evaluate the following: (1) specific
agents and doses of antimicrobials used in surgical antimicrobial prophylaxis; (2) timing of preoperative
and post-operative thromboprophylaxis and the impact on post-operative VTE, and (3) optimal and
efficacious regimens in the successful prevention of PONV.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-9032/8/3/252/
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Pharmacotherapy Elements.
Author Contributions: Conceptualization, E.J., R.P.II and M.G.; methodology, E.J., R.P.II, G.N., K.E., B.K. and
M.G.; writing—original draft preparation, E.J. and R.P.II; writing—review and editing, E.J., R.P.II, G.N., K.E., B.K.
and M.G.; project administration, R.P. and M.G. All authors have read and agreed to the published version of
the manuscript.
Funding: This research received no external funding.
Acknowledgments: The Enhanced Recovery Comparative Pharmacotherapy Collaborative (ERCPC) appreciates
the work of site-basedd contributors and participants.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Gustafsson, U.O.; Scott, M.J.; Hubner, M.; Nygren, J.; Demartines, N.; Francis, N.; Rockall, T.A.;
Young-Fadok, T.M.; Hill, A.G.; Soop, M.; et al. Guidelines for perioperative care in elective colorectal
surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations: 2018. World J. Surg. 2019,
43, 659–695. [CrossRef] [PubMed]
2. Nelson, G.; Bakkum-Gamez, J.; Kalogera, E.; Glaser, G.; Altman, A.; Meyer, L.A.; Taylor, J.S.; Iniesta, M.;
Lasala, J.; Mena, G.; et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery
After Surgery (ERAS) Society recommendations—2019 update. Int. J. Gynecol. Cancer 2019, 29, 651–668.
[CrossRef] [PubMed]
3. Nelson, G.; Altman, A.D.; Nick, A.; Meyer, L.A.; Ramirez, P.T.; Achtari, C.; Antrobus, J.; Huang, J.; Scott, M.;
Wijk, L.; et al. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced
Recovery After Surgery (ERAS®) Society recommendations—Part I. Gynecol. Oncol. 2016, 140, 313–322.
[CrossRef] [PubMed]
4. Nelson, G.; Altman, A.D.; Nick, A.; Meyer, L.A.; Ramirez, P.T.; Achtari, C.; Antrobus, J.; Huang, J.; Scott, M.;
Wijk, L.; et al. Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery
After Surgery (ERAS®) Society recommendations—Part II. Gynecol. Oncol. 2016, 140, 323–332. [CrossRef]
[PubMed]
5. Elias, K.M.; Stone, A.B.; McGinigle, K.; Tankou, J.I.; Scott, M.J.; Fawcett, W.J.; Demartines, N.; Lobo, D.N.;
Ljungqvist, O.; Urman, R.D. The reporting on ERAS compliance, outcomes, and elements research (RECOvER)
checklist: A joint statement by the ERAS® and ERAS® USA Societies. World J. Surg. 2019, 43, 1–8. [CrossRef]
[PubMed]
6. Lassen, K.; Soop, M.; Nygren, J.; Cox, P.; Hendry, P.; Spies, C.; von Meyenfeldt, M.F.; Fearon, K.C.H.;
Revhaug, A.; Norderval, S.; et al. Consensus review of optimal perioperative care in colorectal surgery:
Healthcare 2020, 8, 252 5 of 5
Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch. Surg. 2009, 144, 961–969.
[CrossRef] [PubMed]
7. Lovely, J.; Hyland, S.; Smith, A.; Nelson, G.; Ljungqvist, O.; Parrish, R.H., II. Clinical pharmacist perspectives
for optimizing pharmacotherapy within Enhanced Recovery After Surgery (ERAS®) programs. Int. J. Surg.
2019, 63, 58–62. [CrossRef] [PubMed]
8. Caprini, J.; Arcelus, J.; Hasty, J.; Tamhane, A.; Fabrega, F. Clinical assessment of venous thromboembolic risk
in surgical patients. Semin. Thromb. Hemost. 1991, 17, 304–312. [PubMed]
9. Nelson, D.W.; Simianu, V.V.; Bastawrous, A.L.; Billingham, R.P.; Fichera, A.; Florence, M.G.; Johnson, E.K.;
Johnson, M.G.; Thirlby, R.C.; Flum, D.R.; et al. Thromboembolic complications and prophylaxis patterns in
colorectal surgery. JAMA Surg. 2015, 150, 712–720. [CrossRef] [PubMed]
10. Schmeler, K.; Wilson, G.; Cain, K.; Munsell, M.; Ramirez, P.; Soliman, P.; Nick, A.M.; Frumovitz, M.;
Coleman, R.L.; Kroll, M.H.; et al. Venous thromboembolism (VTE) rates following the implementation
of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies.
Gynecol. Oncol. 2013, 128, 204–208. [CrossRef] [PubMed]
11. Rees, P.; Clouston, H.; Duff, S.; Kirwan, C. Colorectal cancer and thrombosis. Int. J. Colorectal Dis. 2018,
33, 105–108. [CrossRef] [PubMed]
12. Bratzler, D.W.; Dellinger, E.P.; Olsen, K.M.; Perl, T.M.; Auwaerter, P.G.; Bolon, M.K.; Fish, D.N.;
Napolitano, L.M.; Sawyer, R.G.; Slain, D.; et al. Clinical practice guidelines for antimicrobial prophylaxis in
surgery. Am. J. Health-Syst. Pharm. 2013, 70, 195–283. [CrossRef] [PubMed]
13. Apfel, C.; Heidrich, F.; Jukar-Rao, S.; Jalota, L.; Hornuss, C.; Whelan, R.; Zhang, K.; Cakmakkaya, O.
Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br. J. Anaesth. 2012,
109, 742–753. [CrossRef] [PubMed]
14. Gan, T.J.; Belani, K.G.; Bergese, S.; Chung, F.; Diemunsch, P.; Habib, A.S.; Jin, Z.; Kovac, A.L.; Meyer, T.A.;
Urman, R.D.; et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting.
Anesth. Analg. 2020. [CrossRef]
15. Farge, D.; Bounameaux, H.; Brenner, B.; Cajfinger, F.; Debourdeau, P.; Khorana, A.A.; Pabinger, I.;
Solymoss, S.; Douketis, J.; Kakkar, A. International clinical practice guidelines including guidance for
direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with
cancer. Lancet Oncol. 2016, 17, e452–e466. [CrossRef]
16. Hornor, M.A.; Duane, T.M.; Ehlers, A.P.; Jensen, E.H.; Brown, P.S.; Pohl, D.; da Costa, P.M.; Ko, C.Y.;
Laronga, C. American College of Surgeons’ guidelines for the perioperative management of antithrombotic
medication. J. Am. Coll. Surg. 2018, 227, 521–536. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
